Pulmonx Corporation LUNG Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.5%+1.3pp | 74.2%+0.9pp | 73.3%+0.2pp | 73.1%-0.4pp | 73.5%-0.5pp | |
| Operating margin | -58.8%+0.5pp | -59.3%+3.1pp | -62.4%+0.5pp | -62.9%+3.1pp | -66%+2.9pp | |
| Net margin | -60.1%-0.4pp | -59.7%+2.2pp | -61.9%+1.0pp | -62.9%+2.4pp | -65.3%+2.0pp | |
| EBITDA margin | -57.7%+0.5pp | -58.1%+3.0pp | -61.2%+0.3pp | -61.5%+3.0pp | -64.5%+2.6pp | |
| Free cash flow margin | -33.2%+3.1pp | -36.3%-0.7pp | -35.5%-0.2pp | -35.3%+3.9pp | -39.2%+0.2pp | |
| Returns | ||||||
| Return on equity | -86.2%-9.0pp | -77.2%-3.5pp | -73.7%-6.8pp | -66.9%-6.2pp | -60.7%-5.4pp | |
| Return on assets | -39.3%-2.3pp | -37%+0.2pp | -37.1%-1.5pp | -35.6%+0.6pp | -36.2%-3.1pp | |
| Return on invested capital | -92.1%-2.4pp | -89.6%-7.4pp | -82.2%-8.1pp | -74.1%-4.2pp | -69.9%-5.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×+0.1× | |
| Inventory turnover | 8.4×-0.5× | 8.8×-1.5× | 10.3×-1.3× | 11.6×-0.3× | 11.9×+1.7× | |
| Liquidity | ||||||
| Current ratio | 4.9×-0.2× | 5.1×+0.2× | 4.9×-0.5× | 5.3×+0.4× | 5×-0.6× | |
| Quick ratio | 4.7×-0.2× | 4.9×+0.1× | 4.8×-0.5× | 5.3×+0.3× | 4.9×-0.6× | |
| Cash ratio | 3.2×-0.2× | 3.4×+0.2× | 3.2×0.0× | 3.2×+0.7× | 2.5×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×+0.2× | 1×+0.1× | 0.9×+0.1× | 0.8×+0.1× | 0.7×+0.1× | |
| Debt-to-assets | 0.5×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Interest coverage | -15.5×+1.5× | -17×+0.7× | -17.7×-0.5× | -17.2×-0.2× | -17×-0.5× | |
| Per Share | ||||||
| Book value per share | $1.09-17.9% | $1.33-9.3% | $1.47-14.2% | $1.71-12.1% | $1.94-11.4% | |
| Valuation | ||||||
| Market capitalization | $54.91M-43.7% | $91.16M+38.1% | $66.01M-39.2% | $108.49M-59.5% | $267.83M-0.1% | |
| Enterprise value | $50.17M-39.2% | $78.81M+59.1% | $49.53M-46.7% | $93.01M-64.5% | $262.23M+0.7% | |
| Price / sales | 0.6×-0.5× | 1×+0.3× | 0.7×-0.5× | 1.2×-1.9× | 3.1×-0.1× | |
| Price / book | 1.3×-0.2× | 1.7×+0.6× | 1.1×-0.5× | 1.6×-1.9× | 3.4×+0.3× | |
| EV / sales | 0.6×-0.4× | 0.9×+0.3× | 0.5×-0.5× | 1×-2.0× | 3×-0.1× | |
| Free cash flow yield | -50.1%-19.4pp | -36%+13.3pp | -49.3%-19.9pp | -29.5%-16.7pp | -12.8%-0.5pp | |
| Earnings yield | -90.6%-36.0pp | -59.2%+26.7pp | -86%-33.5pp | -52.5%-31.2pp | -21.3%-0.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pulmonx Corporation's profit margins?
- Pulmonx Corporation (LUNG) runs a 75.5% gross margin and a -58.8% operating margin, with a -60.1% net margin.
- Where do Pulmonx Corporation's ratios come from?
- Every ratio is computed from Pulmonx Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
